Clinical trials: Psychiatric Illness
Insomnia Disorder
A Study of HS-10506 in Chinese Patients With Insomnia Disorder
The primary purpose of this phase 3 study is to evaluate the safety and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) and wakefulness after sleep onset (WASO) measured by polysomnography…
- Trial name
- NCT07587385
- Testing
- HS-10506
- Volunteers
- 732 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Alzheimer Disease
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
- Trial name
- NCT06427668
- Testing
- SPG302
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Spinogenix
Opioid-Induced Constipation (OIC)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative…
- Trial name
- NCT01323790
- Testing
- NKTR-118
- Where
- 120 sites in United States, Belgium and 6 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Mild Cognitive Impairment
Multidisciplinary Intervention for Mild Cognitive Impairment
The purpose of this investigation is to conduct a series of case studies on the impact of a novel functional medicine approach to improving cognitive skills, brain structure, and daily functioning for participants with Mild…
- Trial name
- (MCI) (NCT02943187)
- Testing
- Cognitive training, Nutrition
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Gibson Institute of Cognitive Research
Posttraumatic Stress Disorder
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least severe PTSD. The main question it aims to answer is: Do three sessions of MDMA-assisted therapy reduce PTSD…
- Trial name
- NCT03537014
- Testing
- Therapy, midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Resilient Pharmaceuticals
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00210704
- Testing
- Dapoxetine
- Volunteers
- 1,067 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Opioid Related Disorder
Transfer of Subjects From Subutex/Suboxone to RBP-6300
This study is designed to determine if opioid dependent subjects who are already receiving Subutex and/or Suboxone can transfer to RBP-6300.
- Trial name
- NCT01582347
- Testing
- RBP-6300, Subutex®/Suboxone®
- Where
- 15 sites in Austria, Czechia and 2 more
- Volunteers
- 143 people
- Sponsor
- Indivior Inc.
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00337285
- Testing
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Where
- 45 sites in United States
- Volunteers
- 349 people
- Sponsor
- New River Pharmaceuticals
Alzheimer's Disease
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00607308
- Testing
- PF-04360365
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Pfizer
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Weight Gain
Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study. Approximately 78 subjects (39 per treatment group) will be randomized into this 16 week study.
- Trial name
- NCT00428168
- Testing
- Betahistine
- Where
- 10 sites in Canada, Israel
- Volunteers
- 36 people
- Sponsor
- OBEcure Ltd.
Alzheimer's Disease
A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's Disease (AD) or Mild to Moderate AD.
- Trial name
- NCT02127476
- Testing
- KHK6640
- Where
- 9 sites in Belgium, Finland and 3 more
- Volunteers
- 57 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cannabis
Intervening to Prevent Youth Access to Marijuana Phase II
The legalization of recreational marijuana use and sales in Alaska, Colorado, Oregon, and Washington State is a dramatic change in U.S.
- Trial name
- NCT03073291
- Testing
- Responsible Marijuana Vendor Training
- Where
- 2 sites in United States
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Trial name
- NCT00035048
- Testing
- aprepitant
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Disorder, Depression
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT01727726
- Testing
- Brexpiprazole, Seroquel XR
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 2,182 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Schizophrenia
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of…
- Trial name
- NCT01150448
- Testing
- Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B
- Where
- 28 sites in United States, Belgium and 8 more
- Volunteers
- 212 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Autistic Disorder
An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)
The primary study objective is to evaluate the efficacy of Vayarin_005 on ASD related symptoms in children.
- Trial name
- NCT02222285
- Testing
- Medical Food : Vayarin_005
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Enzymotec
Healthy Volunteer, Autistic Disorder, Asperger's Syndrome
A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome
This multi-center, non-drug study will explore the relationship between exploratory biomarkers and functional dimensions in male adult individuals with Autistic Disorder or Asperger's Syndrome and healthy volunteer controls.
- Trial name
- NCT01669889
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.
- Trial name
- NCT02991235
- Testing
- PRJ212
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Bioiberica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.